80results about How to "Inhibition of catalytic activity" patented technology

The present invention provides a compound of formula I:

Disclosed herein are carbonyl compounds of Formula I as described herein.

Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.

It is an object of the present invention to provide a method of producing a rutile titanium dioxide fine particle having a high ultraviolet protection property and high transparency for visible light. The present invention provides a method of producing a rutile titanium dioxide fine particle, comprising the steps of (1) treating titanium dioxide hydrate with at least one of a basic compound selected from the group consisting of hydroxides of alkali metal and hydroxides of alkaline-earth metal, and (2) treating the compound obtained by the step (1) with a carboxylic acid group-containing compound and an inorganic acid.

A process for the hydrotreating of fuels with co-production of hydrogen during operation of the process, which enables i.e. reduced need of make-up hydrogen in the hydrotreating stage. The hydrocarbon fuel introduced to the hydrotreatment stage is a fuel containing renewable organic material which generates carbon monoxide during operation of the process. The carbon monoxide is then converted to hydrogen in the recycle loop by a water gas shift stage.

The invention relates to a method of effectively producing 1, 3-propylene glycol by changing the membrane permeability, which adds nonionics to change the membrane permeability, effectively promotes the cell growth, and increases the concentration of 1, 3-propylene glycol which is the finished product of fermentation. The utility model has the technical process that as follows: adding the second-class germ culture into the fermentation culture; adding nonionics which can improve the membrane permeability to the fermentation culture; the nonionics reduce the resistance of the oxygen and nutrient substance from entering the cell, promote the cell growth, enhance the secreting of metabolite to the extra-cellular area, reduce the accumulation of metabolite in cell, and facilitate the elimination of inhibition of product and sub product, in particular the inhibition of cell growth and cell catalytic activity by 1, 3-propylene glycol. The concentration of the fermentation product--1, 3-propylene glycol is increased by 10 to 70 percent. With simple technical process and low production cost, the invention is easy to be industrially applied.

The invention provides a method for operating a reformed gas production apparatus with which it is possible to achieve a high reforming efficiency while preventing a drop in catalyst activity due to the deposition of carbon. The reformed gas production method uses a reforming catalyst to reform a fuel that contains a hydrocarbon having at least two carbon atoms to produce a reformed gas that includes methane, hydrogen, and carbon monoxide. With this method, a fluid that includes the fuel, at least one of steam and a carbon dioxide-containing gas, and an oxygen-containing gas, is supplied to a reforming reaction region, and with the thermal decomposition index temperature of the fuel, which is determined by the type and the concentration of the hydrocarbons having at least two carbon atoms that make up the fuel, serving as an upper limit temperature of the reforming reaction region, the fluid is brought into contact with the reforming catalyst to produce the reformed gas.

The invention provides a palladium/alkali metal compound supported catalyst and a preparation method and application thereof. The catalyst is composed of a supporter and an active component supported on the supporter. The supporter is active carbon. The active component comprises elemental palladium and an alkali metal compound. Based on the mass of the supporter active carbon, the supporting amount of the elemental palladium is 0.25-15.0wt%, and the theoretical supporting amount of alkali metal elements in the alkali metal compound is 0.01-5.0wt%. The catalyst can be applied to a catalytic hydrogenation reaction of a haloaromatic nitrocompound and/or an aromatic nitro compound. The catalyst is high in catalytic activity and easy to recycle and use indiscriminately, no dehalogenation inhibitor needs to be added when the catalyst is applied to the catalytic hydrogenation reaction of the haloaromatic nitrocompound, and the reaction conversion rate and the product selectivity are still excellent on the premise of keeping the high reaction speed.

This invention relates to a method for selecting PDE IV inhibitors which have a salutory therapeutic index, and to compounds having these properties.

The invention discloses novel N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds with the general formula disclosed in the specification, which have the activity of inhibiting carbonic anhydrase and further achieve the effect of resisting tumor metastasis and invasion. The compounds structurally have the three active segments sulfamine, substituted glucosamine and thiocarbamide, and the three active segments and Zn<2+> ions in the carbonic anhydrase form coordinate bonds, thereby inhibiting the catalytic activity of the enzyme and performing the function of resisting tumor metastasis and invasion. Thus, the compounds have application potential in the aspect of antitumor drugs. In the general formula, R is defined in the specification.

A polyester polymer comprising alkylene arylate units, said polymer having an It.V. of at least 0.72 dl/g, a vinyl ends concentration of at least 0.8 microequivalents per gram, an AA generation rate of less than 20 ppm are prepared by addition of a catalyst deactivator either late in the polycondensation or upon remelting of a solid polyester polymer.

A catalyst body of the present invention includes: a porous carrier in which a large number of aggregate particles containing a main component of a nonoxide ceramic are bonded to one another while a large number of pores are disposed; and a catalyst layer carried on the porous carrier and containing a compound of an alkali metal, wherein the porous carrier has an oxide film unavoidably formed on a part of the surface of the aggregate particles, and an oxide film protective layer formed of a material which does not form low-melting glass with the alkali metal is further disposed between the oxide film and the catalyst layer in such a manner as to coat at least a part of the oxide film.

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Provided is an exhaust gas purification catalyst in which the performance of a catalyst metal can be brought out properly, the purification catalyst boasting excellent purification performance during warm-up of an internal combustion engine. The exhaust gas purification catalyst 10 is provided with a substrate 1 and a catalyst layer. A leading end section 1a positioned upstream in the direction of exhaust gas flow (arrow) has a portion in which the flow rate of exhaust gas is relatively high and a portion in which the flow rate of exhaust gas is relatively low during warm-up of the internal combustion engine. The catalyst, layer in the portion of relatively high flow rate of exhaust gas has a high density section 6 in which a noble metal, is supported at relatively high density. The high density section 6 is formed to be shorter than the total length of the exhaust gas purification catalyst 10 from the leading end section 1a in the direction of exhaust gas flow.

The invention discloses a glow-type chemiluminescence sensor constructed based on hydrogel and a preparation method and application thereof. The invention also discloses an analytical method for detecting organophosphorus pesticides by using the glow-type chemiluminescence sensor constructed based on hydrogel, which comprises the following steps: (1) preparing ABEI/CO<2+>/CS hydrogel; (2) preparing an MOF-Pt material; and (3) mixing an organophosphorus pesticide with acetylcholinesterase for reaction to obtain mixed solution, adding chlorinated acetylcholine solution, choline oxidase solutionand PBS buffer solution into the mixed solution for reaction to obtain a mixture, adding the MOF-Pt and the mixture into the hydrogel, and measuring the chemiluminescence intensity with a chemiluminescence imager. The analytical method does not need the aid of precise and expensive experimental instruments, has no strict and complex experimental operation process, greatly reduces the detection cost of organophosphorus pesticides, and has the advantages of high sensitivity, short detection time, long luminescent time, high-throughput detection and the like.

The invention relates to a blood ammonia (AMM) detection reagent and in particular relates to a high-stability single-reagent liquid-state blood ammonia (AMM) detection reagent. The reagent is mainly prepared from main substances including a buffering solution, LDH (Lactate Dehydrogenase), a heavy metal ion chelating agent, an ionic balance agent, a preservative, alpha-KG, NADH.NA2, a surfactant, a protecting agent and the like. According to the reagent, a single reagent of glutamate dehydrogenase two-point method and kinetic method is established; the utilization operation is effectively simplified and the stability of effective components of a product is guaranteed; the metal chelating agent is properly selected so that the inhibition, caused by the heavy metal ions, on the activity of an enzyme in the reagent is effectively removed; interference on the enzyme is not caused; the protecting agent is properly added so that the stability of the enzyme and the stability of key substrates in the reagent are effectively protected; the substances are added so that the stability of a single-reagent product provided by the invention is effectively guaranteed and the reagent is greatly convenient for utilization and popularization clinically.

The invention provides a photoresist and a preparation method and application thereof. The photoresist is prepared from, by weight, 40-80 parts of polyester acrylic resin, 2-10 parts of pigment, 6-12 parts of dye, 8-25 parts of reactive diluent, 2-8 parts of photoinitiator and 1-5 parts of dispersing agent. The photoresist has the advantages that the defects that an existing photoresist can not be used for printing and is extremely large in viscosity and the drying speed can not be precisely controlled are overcome, the photoresist has the advantages of being bright in color and luster, high in transparency, firm in adhesion force, high in curing speed, stable in performance, high in storage performance, excellent in weather resistance and corrosion resistance and the like, and the photoresist is suitable for the emerging industry of printing photoresists.

The use of a eosinophil secondary granules basic protein and any functional fragments thereof, and preferably, the use of Major Basic Protein (MBP) purified from eosinophils, as a natural heparanase inhibitor. Also, methods for the inhibition of the catalytic activity of heparanase using MBP, and to methods and compositions for the treatment of heparanase associated pathologic disorders. These methods and composition are particularly useful for the treatment of angiogenesis, tumor formation, tumor progression or tumor metastasis.